Denosumab Therapy for Osteoporosis

Evidence Supporting Medical Necessity

The American College of Clinical Oncology recommends denosumab 60 mg subcutaneous injection every 6 months for patients with age-related osteoporosis who have demonstrated clinical benefit, as evidenced by an 8% improvement in lumbar spine BMD, with a strength of evidence level of high 1, 2
Patients who have received more than 24 months of denosumab therapy and have no adverse effects, such as the patient in question with minimal neck and low back pain (rated 1/10), may continue therapy, according to the Journal of Clinical Oncology 1, 2
The patient's FRAX score of 12.8% for major osteoporotic fracture and 1.1% for hip fracture exceeds treatment thresholds, indicating a high risk of fracture, as reported by the Journal of Clinical Oncology 4

Denosumab has been shown to reduce vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20%, as demonstrated in the FREEDOM trial, with a strength of evidence level of high 2

The National Osteoporosis Foundation recommends 1000-1200 mg calcium daily and at least 800-1000 IU vitamin D daily for patients on denosumab, which is consistent with the patient's regimen of 1200 mg calcium and 2000 IU vitamin D, as reported by the Journal of Clinical Oncology 4

Discontinuation of denosumab therapy requires immediate transition to alternative antiresorptive therapy, such as high-dose bisphosphonate, to prevent rebound vertebral fractures, as recommended by Praxis Medical Insights, with a strength of evidence level of moderate 3